V
VERA THERAPEUTICS INC
NASDAQ: VERA (Vera Therapeutics, Inc.)
Kemas kini terakhir: 1 jam lalu24.00
0.35 (1.48%)
| Penutupan Terdahulu | 23.65 |
| Buka | 23.75 |
| Jumlah Dagangan | 629,758 |
| Purata Dagangan (3B) | 1,812,286 |
| Modal Pasaran | 1,530,580,736 |
| Harga / Buku (P/B) | 2.81 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 Aug 2025 |
| EPS Cair (TTM) | -3.00 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.18% |
| Nisbah Semasa (MRQ) | 27.68 |
| Aliran Tunai Operasi (OCF TTM) | -155.26 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -97.14 M |
| Pulangan Atas Aset (ROA TTM) | -23.46% |
| Pulangan Atas Ekuiti (ROE TTM) | -39.49% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Vera Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
2.6
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | 2.5 |
| Volatiliti Harga | 4.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 2.0 |
| Purata | 2.60 |
|
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.97% |
| % Dimiliki oleh Institusi | 112.39% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Avoro Capital Advisors Llc | 31 Mar 2025 | 5,701,900 |
| Price T Rowe Associates Inc /Md/ | 31 Mar 2025 | 4,754,832 |
| Sofinnova Investments, Inc. | 31 Mar 2025 | 2,793,987 |
| Commodore Capital Lp | 31 Mar 2025 | 2,561,782 |
| Vestal Point Capital, Lp | 31 Mar 2025 | 2,500,000 |
| Kynam Capital Management, Lp | 31 Mar 2025 | 2,400,000 |
| Holocene Advisors, Lp | 31 Mar 2025 | 2,199,292 |
| Eversept Partners, Lp | 31 Mar 2025 | 1,898,804 |
| First Light Asset Management, Llc | 31 Mar 2025 | 1,175,879 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 100.00 (Cantor Fitzgerald, 316.67%) | Beli |
| Median | 70.00 (191.67%) | |
| Rendah | 26.00 (Wedbush, 8.33%) | Pegang |
| Purata | 66.50 (177.08%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 27.18 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 02 Jun 2025 | 85.00 (254.17%) | Beli | 31.74 |
| 05 May 2025 | 75.00 (212.50%) | Beli | 25.53 | |
| Scotiabank | 02 Jun 2025 | 55.00 (129.17%) | Beli | 31.74 |
| Cantor Fitzgerald | 07 May 2025 | 100.00 (316.67%) | Beli | 22.62 |
| Wedbush | 07 May 2025 | 26.00 (8.33%) | Pegang | 22.62 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ENRIGHT PATRICK G | 22.12 | - | 250,000 | 5,450,265 |
| Jumlah Keseluruhan Kuantiti Bersih | 250,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 5,450,265 | |||
| Purata Pembelian Keseluruhan ($) | 22.12 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| ENRIGHT PATRICK G | Pengarah | 24 Jun 2025 | Beli (+) | 40,607 | 22.58 | 916,906 |
| ENRIGHT PATRICK G | Pengarah | 23 Jun 2025 | Beli (+) | 209,393 | 21.65 | 4,533,358 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 09 Jun 2025 | Pengumuman | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 04 Jun 2025 | Pengumuman | Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference |
| 03 Jun 2025 | Pengumuman | Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans |
| 02 Jun 2025 | Pengumuman | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy |
| 09 May 2025 | Pengumuman | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 06 May 2025 | Pengumuman | Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results |
| 09 Apr 2025 | Pengumuman | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |